See what’s happening at FerGene
New Analysis of Phase 3 study presented at SUO 2020
New Data Analyses from Phase 3 Study of Investigational Gene Therapy Nadofaragene Firadenovec...
FerGene announces Landmark Phase 3 study published in The Lancet Oncology
Landmark Study in Non-Muscle Invasive Bladder Cancer Evaluating Breakthrough Investigational Gene...
FerGene Appoints Top Biotech Leaders to Executive Team
Gene therapy company focused on uro-oncology continues to expand operations and prepare for the...
FerGene Provides Update on BLA for Nadofaragene Firadenovec
The U.S. Food and Drug Administration (FDA) has issued a response to the Biologics License...
FerGene to present bladder cancer data at 2020 ASCO Genitourinary Cancers Symposium
Data highlight a need for bladder-sparing therapies to improve outcomes for patients with...
FerGene Appoints David Meek Chief Executive Office
CAMBRIDGE, Mass. - December 19, 2019 FerGene, a new gene therapy company launched by Ferring...
Media inquiries